MX2018014185A - Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. - Google Patents
Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa.Info
- Publication number
- MX2018014185A MX2018014185A MX2018014185A MX2018014185A MX2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A MX 2018014185 A MX2018014185 A MX 2018014185A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- pure
- receptor antagonists
- acetylcholinesterase inhibitors
- adjunct
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 2
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 2
- 239000002464 receptor antagonist Substances 0.000 title abstract 2
- 229940044551 receptor antagonist Drugs 0.000 title abstract 2
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se relaciona con antagonistas puros del receptor 5-HT6, o su(s) sal(es) farmacéuticamente aceptable(s) en combinación con o como adyuvante de inhibidores de la acetilcolinesterasa, y con su uso en el tratamiento de trastornos cognitivos. La invención además provee la composición farmacéutica que contiene dicha combinación.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017205 | 2016-05-18 | ||
| PCT/IB2016/054673 WO2017199071A1 (en) | 2016-05-18 | 2016-08-03 | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018014185A true MX2018014185A (es) | 2019-02-25 |
| MX381768B MX381768B (es) | 2025-03-13 |
Family
ID=56940098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014185A MX381768B (es) | 2016-05-18 | 2016-08-03 | Combinación de antagonistas puros del receptor 5-ht6 con inhibidores de la acetilcolinesterasa. |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US11458135B2 (es) |
| EP (1) | EP3484467B1 (es) |
| JP (1) | JP6606299B2 (es) |
| KR (1) | KR102015484B1 (es) |
| CN (2) | CN114642667A (es) |
| AU (1) | AU2016407427B2 (es) |
| BR (1) | BR112018073419A2 (es) |
| CA (1) | CA3023819C (es) |
| CY (1) | CY1123013T1 (es) |
| DK (1) | DK3484467T3 (es) |
| EA (1) | EA036347B1 (es) |
| ES (1) | ES2796181T3 (es) |
| HR (1) | HRP20200872T1 (es) |
| HU (1) | HUE050819T2 (es) |
| IL (1) | IL262921B (es) |
| LT (1) | LT3484467T (es) |
| MA (1) | MA45639B1 (es) |
| MD (1) | MD3484467T2 (es) |
| ME (1) | ME03731B (es) |
| MX (1) | MX381768B (es) |
| NZ (1) | NZ748280A (es) |
| PL (1) | PL3484467T3 (es) |
| PT (1) | PT3484467T (es) |
| RS (1) | RS60422B1 (es) |
| SG (1) | SG11201809856SA (es) |
| SI (1) | SI3484467T1 (es) |
| SM (1) | SMT202000292T1 (es) |
| WO (1) | WO2017199071A1 (es) |
| ZA (1) | ZA201807468B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111084768A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 吉非罗齐及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| CN111084776A (zh) * | 2018-10-24 | 2020-05-01 | 中国科学院昆明动物研究所 | 匹立尼酸及其衍生物用于治疗和/或预防神经退行性疾病的用途 |
| JP7556031B2 (ja) * | 2019-12-02 | 2024-09-25 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者の行動心理学的症状の治療 |
| ES3036880T3 (en) * | 2019-12-02 | 2025-09-25 | Suven Life Sciences Ltd | Combinations of masupirdine with donepezil or memantine for treating behavioral and psychological symptoms in patients with dementia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1581492E (pt) | 2002-11-28 | 2008-09-19 | Suven Life Sciences Ltd | Indoles n-arilsulfonil-3-substituídos possuindo afinidade de receptor de serotonina, processo para a sua preparação e composição farmacêutica contendo os mesmos |
| MXPA05005808A (es) * | 2002-12-18 | 2005-09-08 | Suven Life Sciences Ltd | Indoles tetraciclicos sustituidos en la posicion 3 que tienen afinidad por el receptor de la serotonina. |
| PE20071143A1 (es) | 2006-01-13 | 2008-01-20 | Wyeth Corp | Composicion farmaceutica que comprende un inhibidor de acetilcolinesterasa y un antagonista 5-hidroxitriptamina-6 |
| JP2009541423A (ja) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ |
| AR061637A1 (es) | 2006-06-26 | 2008-09-10 | Epix Delaware Inc | Composiciones y metodos de tratamiento de trastornos del snc |
| JO3459B1 (ar) | 2012-09-09 | 2020-07-05 | H Lundbeck As | تركيبات صيدلانية لعلاج مرض الزهايمر |
| CN105814020B (zh) | 2013-12-02 | 2018-04-17 | 苏文生命科学有限公司 | 用于大规模生产1‑[(2‑溴苯基)磺酰基]‑5‑甲氧基‑3‑[(4‑甲基‑1‑哌嗪基)甲基]‑1h‑吲哚二甲磺酸盐一水合物的方法 |
| TR201903344T4 (tr) * | 2014-08-16 | 2019-04-22 | Suven Life Sciences Ltd | 1-[(2-bromofenil) sülfonil]-5-metoksi-3- [(4-metil-1-piperazinil) metil]-1H-indol dimesilat monohidratın aktif metaboliti ve aktif metabolitin dimesilat dihidrat tuzu. |
-
2016
- 2016-08-03 SG SG11201809856SA patent/SG11201809856SA/en unknown
- 2016-08-03 SI SI201630791T patent/SI3484467T1/sl unknown
- 2016-08-03 PL PL16766622T patent/PL3484467T3/pl unknown
- 2016-08-03 RS RS20200635A patent/RS60422B1/sr unknown
- 2016-08-03 HR HRP20200872TT patent/HRP20200872T1/hr unknown
- 2016-08-03 EA EA201892529A patent/EA036347B1/ru unknown
- 2016-08-03 MA MA45639A patent/MA45639B1/fr unknown
- 2016-08-03 MD MDE20190594T patent/MD3484467T2/ro unknown
- 2016-08-03 NZ NZ748280A patent/NZ748280A/en unknown
- 2016-08-03 LT LTEP16766622.1T patent/LT3484467T/lt unknown
- 2016-08-03 BR BR112018073419-5A patent/BR112018073419A2/pt not_active Application Discontinuation
- 2016-08-03 CA CA3023819A patent/CA3023819C/en active Active
- 2016-08-03 CN CN202210321209.2A patent/CN114642667A/zh active Pending
- 2016-08-03 KR KR1020187035983A patent/KR102015484B1/ko active Active
- 2016-08-03 JP JP2018559336A patent/JP6606299B2/ja active Active
- 2016-08-03 US US16/099,161 patent/US11458135B2/en active Active
- 2016-08-03 HU HUE16766622A patent/HUE050819T2/hu unknown
- 2016-08-03 AU AU2016407427A patent/AU2016407427B2/en active Active
- 2016-08-03 ES ES16766622T patent/ES2796181T3/es active Active
- 2016-08-03 CN CN201680085574.0A patent/CN109069468A/zh active Pending
- 2016-08-03 PT PT167666221T patent/PT3484467T/pt unknown
- 2016-08-03 EP EP16766622.1A patent/EP3484467B1/en active Active
- 2016-08-03 MX MX2018014185A patent/MX381768B/es unknown
- 2016-08-03 ME MEP-2020-109A patent/ME03731B/me unknown
- 2016-08-03 DK DK16766622.1T patent/DK3484467T3/da active
- 2016-08-03 WO PCT/IB2016/054673 patent/WO2017199071A1/en not_active Ceased
- 2016-08-03 SM SM20200292T patent/SMT202000292T1/it unknown
-
2018
- 2018-11-07 ZA ZA2018/07468A patent/ZA201807468B/en unknown
- 2018-11-11 IL IL262921A patent/IL262921B/en active IP Right Grant
-
2020
- 2020-05-29 CY CY20201100489T patent/CY1123013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002321A (es) | Nuevos metodos. | |
| PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2021002322A (es) | Nuevos metodos. | |
| PH12018500586A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
| MD20170016A2 (ro) | Compuşi aminopirimidinici ca inhibitori JAK | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| MX2017014192A (es) | Composiciones y metodos de tratamiento de una enfermedad neurodegenerativa. | |
| NZ736055A (en) | Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators | |
| MX2020010568A (es) | Derivados de urea ciclica fusionada como antagonista de crhr2. | |
| TW201713341A (en) | Compositions and methods of treating a neurodegenerative disease | |
| MX368214B (es) | Compuestos de amida como agonistas del receptor de la 5-hidroxitriptamina 4 (5-ht4). | |
| MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
| MY201535A (en) | Therapeutic compounds | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| MX2018014185A (es) | Combinacion de antagonistas puros del receptor 5 ht6 con inhibidores de la acetilcolinesterasa. | |
| NZ755637A (en) | Compounds and their use in the treatment of schistosomiasis | |
| MX2014000963A (es) | Derivados de carboxamida y urea aromaticos biciclicos sustituidos como ligandos del receptor de vanilloide. | |
| PH12016502236A1 (en) | (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine | |
| AU2016407426A1 (en) | Triple combination of pure 5-HT6 receptor antagonists, Acetylcholinesterase inhibitors and NMDA receptor antagonist | |
| MX378799B (es) | Combinación de antagonistas del receptor 5-ht6 puro con un antagonista del receptor nmda. | |
| PH12017501736A1 (en) | Indole derivatives | |
| PH12016502480A1 (en) | Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases | |
| PH12016502107A1 (en) | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders | |
| MX2018004774A (es) | Derivados de morfolina sustituidos que tienen actividad contra el dolor. |